The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study.
Bram VerstocktSeverine VermeireLaurent Peyrin-BirouletRebecca A MosigBrian G FeaganJean-Frederic ColombelBritta SiegmundFlorian RiederStefan SchreiberAndres YarurRemo PanaccioneMarla DubinskySimon LichtigerFabio CataldiSilvio DanesePublished in: Journal of Crohn's & colitis (2023)
NX-13 was generally safe and well tolerated with early signs of rapid symptom and endoscopic improvement. This novel mechanism of action warrants further investigation. ClinicalTrials.gov: NCT04862741.